07:51 AM EDT, 09/18/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended for approval Hungary-based Gedeon Richter's arthritis drug Inijaq, according to a Friday notice. Inijaq, a generic of Pfizer's (PFE.F) Xeljanz, is intended to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis and juvenile idiopathic arthritis. Xeljanz has been authorized in the EU since March 2017. The drug is subject to final approval from the European Commission.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.